# Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

> **NCT05217537** · PHASE1 · COMPLETED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 23 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Omadacycline Injection [Nuzyra]
- **DRUG:** Omadacycline Oral Tablet

## Key facts

- **NCT ID:** NCT05217537
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-06
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217537, "Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05217537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*